MidDiagnosed 2026-09-17 15:18:41 KSTCCAPRAI Stock Diagnostic ReportOppenheimer reiterates Capricor stock rating ahead of trial dataAhead of the clinical data announcement, Oppenheimer reaffirmed its investment rating on Capricor, but with limited new catalysts, the stock’s direction is viewed as neutral.View Source Article ↗ AI CATALYST SCORE45 / 100Score computed by Sentinel V12REFERENCE PRICENot measuredReference entry price at analysis time 👍 0🔥 0🤔 0🔗 0𝕏f🔗📤